Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07404137 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT07404137 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 26 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07404137, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.
Conditions Studied
Interventions
- DRUG Zibotentan/Dapagliflozin FDC
Study Locations (1)
California
- Research Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-02-16 |
| Est. Completion | 2026-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07404137
The ClinicalTrials.gov registry entry for NCT07404137 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (60% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which Zibotentan/Dapagliflozin FDC is the first listed.
NCT07404137 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07404137 about?
NCT07404137 is a clinical study titled "A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food". The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.
What is the current status of trial NCT07404137?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2026-02-16. Estimated completion is 2026-04-13.
What conditions does trial NCT07404137 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07404137?
The interventions under investigation include: Zibotentan/Dapagliflozin FDC (DRUG).
Who is sponsoring clinical trial NCT07404137?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07404137 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
-
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.